Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs.

Prinzi N, Raimondi A, Maccauro M, Milione M, Garanzini E, Torchio M, Corti F, Nichetti F, Russo GL, Giacomelli L, Mazzaferro V, Bartolomeo MD, Seregni E, Braud F, Pusceddu S.

Future Oncol. 2019 Sep;15(26):3015-3024. doi: 10.2217/fon-2019-0138. Epub 2019 Aug 19.

PMID:
31424273
2.

Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer.

Hill AG, Findlay MP, Burge ME, Jackson C, Alfonso PG, Samuel L, Ganju V, Karthaus M, Amatu A, Jeffery M, Bartolomeo MD, Bridgewater J, Coveler AL, Hidalgo M, Kapp AV, Sufan RI, McCall BB, Hanley WD, Penuel EM, Pirzkall A, Tabernero J.

Clin Cancer Res. 2018 May 15;24(10):2276-2284. doi: 10.1158/1078-0432.CCR-17-0646. Epub 2018 Mar 5.

3.

Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis.

Cremolini C, Antoniotti C, Pietrantonio F, Berenato R, Tampellini M, Baratelli C, Salvatore L, Marmorino F, Borelli B, Nichetti F, Bironzo P, Sonetto C, Bartolomeo MD, Braud F, Loupakis F, Falcone A, Di Maio M.

Cancer Res Treat. 2017 Jul;49(3):834-845. doi: 10.4143/crt.2016.249. Epub 2016 Nov 15. Review.

Supplemental Content

Loading ...
Support Center